Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chengdu Wiskin Biomedical Technology

Request full access

Developing mRNA therapeutics and cancer vaccines

ChinaFounded 2021Biotech & Life Sciences

About Chengdu Wiskin Biomedical Technology

Chengdu Wiskin Biomedical Technology Co., Ltd., also known as WestGene Biopharma, is a biopharmaceutical company established in July 2021. It was co-founded by Dr. Wei Yuquan, an academician of the Chinese Academy of Sciences, and Dr. Xiangrong Song, a scientist with over a decade of experience in mRNA drug research and development who also serves as the CEO. The company is focused on the research and development of innovative mRNA drugs and vaccines.

WestGene's primary work involves developing a pipeline of over 20 mRNA therapeutic products targeting a range of diseases, including cancer, infectious diseases, obesity, and aging. A key product is WGc-043, an mRNA therapeutic cancer vaccine designed to target Epstein-Barr Virus (EBV)-related cancers. In 2024, WGc-043 received Investigational New Drug (IND) approvals from both the U.S. FDA and China's National Medical Products Administration (NMPA), marking a significant milestone for the company. The vaccine works by stimulating the patient's immune system to produce T-cells and antibodies to fight cancer cells and has shown promising safety and efficacy in investigator-initiated trials for nasopharyngeal carcinoma and NK/T-cell lymphoma.

The company's business model appears to be centered on the research, development, and future commercialization of its drug pipeline. WestGene is open to various forms of commercial collaboration, including pipeline licensing, co-development, and technology licensing. WestGene has secured significant funding, including a Series A round of $41.8 million in 2023, to support clinical trials and further research. The company has established five key R&D platforms, including platforms for cancer therapy vaccines, protein replacement drugs, gene editing technology, and preventive vaccines, and has developed a patented LNP delivery system for its mRNA products.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
25.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2023 $21M $84M Tigermed · Hangzhou Tigermed · Chengdu Guanghua Wutong Equity Investment · Konruns Pharmaceutical ↗
SERIES A✓Equity / VC Dec 2022 $21M $83M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Chengdu Wiskin Biomedical Technology website traffic

Latest recorded traffic for Chengdu Wiskin Biomedical Technology is 350 monthly website visits, up 288.9% over the last three months. Chengdu Wiskin Biomedical Technology's team declined 50% over the past year.

Latest monthly visits350 3-month web change+288.9% 1-year team growth-50%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chengdu Wiskin Biomedical Technology in its local ecosystem

Live from Dealroom

The Chengdu Wiskin Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Tigermed
  • Hangzhou Tigermed
  • Chengdu Guanghua Wutong Equity Investment
  • Konruns Pharmaceutical
Employees 1 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chengdu Wiskin Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chengdu Wiskin Biomedical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.